Drug Profile
Research programme: janus kinase inhibitors - Rigel Pharmaceuticals/Aclaris Therapeutics
Alternative Names: R 333; R 548; R 723Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Developer Aclaris Therapeutics; Rigel Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alopecia areata; Haematological malignancies
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Alopecia areata in USA (PO)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Alopecia areata in USA (PO)
- 23 Mar 2016 Aclaris Therapeutics has patent protection for Janus Kinase inhibitor in the Us and outside the US (Aclaris Therapeutics 10-K; March 2016)